This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Management
-
Sarah Howell, Ph.D., Chief Executive Officer and Executive Director
Sarah Howell has been Chief Executive Officer of Arecor since 2015.
READ MORE ↓READ LESS ↑Through her leadership, Arecor has grown significantly into a publicly listed clinical stage biopharmaceutical company. Since her appointment, Sarah has led Arecor through a period of continued growth and transformation, playing an instrumental role in progressing its proprietary pipeline and strengthening important collaborations with global partners.
Sarah has a background in clinical and commercial pharmaceutical product development, manufacturing, supply and licensing across a range of product types and therapeutic areas, with previous senior roles in the pharmaceutical industry including Vice President CMC & Technical Development at BTG Plc., and Director of Outsourced Manufacturing at UCB-Celltech. Sarah holds a BSc in Chemistry from the University of Birmingham and a Ph.D. in Physical Organic Chemistry from the University of St Andrews.
-
David Ellam, Interim Chief Financial Officer
David is an experienced finance professional and chartered accountant, with over two decades of experience in the life sciences industry.
READ MORE ↓READ LESS ↑David is an experienced finance professional and chartered accountant, with over two decades of experience in the life sciences industry.
He has held CFO roles at numerous healthcare companies including Juvenescence, a life sciences company developing therapies to modify ageing and increase healthy human lifespan, Silence Therapeutics, a biotechnology company harnessing the body’s natural mechanism of RNA interference (RNAi) and, more recently, Sixfold Bioscience, a company focused on RNA delivery using AI/ML. Early in his career, he qualified as an accountant at PwC, transitioning to a variety of financial and internal audit roles at companies including Smith & Nephew.
-
Jan Jezek, Ph.D., Chief Scientific Officer
Jan Jezek has been Chief Scientific Officer of Arecor since 2007 and has led R&D for the proprietary protein stabilisation technologies of the company’s Arestat™ platform and their application to commercial therapeutic products. Jan is responsible for R&D activities, platform development and IP strategy.
READ MORE ↓READ LESS ↑Previously, he was a Principal Scientist at Insense Limited, a spin-out from Unilever, where he was responsible for the development of novel medical devices, taking them from concept to market.
Jan holds a joint Doctorate from the University of Bedfordshire and the University of Chemical Technology, Prague. He is a member of the Scientific Advisory Board of the Centre of Excellence in Biopharmaceuticals (University of Manchester) and is an active member of the Formulation Science & Technology Group (FSTG) at the Royal Society of Chemistry and the Biopharmaceutical Group at the Academy of Pharmaceutical Sciences (APS).
-
David Gerring, Senior VP, Development
David has 15 years’ experience in pharmaceutical product and analytical development, as well as significant regulatory and quality experience. He is VP, Development at Arecor, with a wide range of responsibilities, including: scientific strategy, project management, facilities, health & safety, quality and client procurement, grant and internal product development management.
READ MORE ↓READ LESS ↑He has held senior roles at Immunocore and Emergent BioSolutions and his experience includes 5 years at UCB, whilst in a scientific and regulatory capacity. There, he focused on the development and successful licensure of Cimzia. He headed up process and analytical development at BTG, managing CMC for several recombinant products, including successful INDs and licensures.
-
Helen Parris, Senior VP, Commercial and General Manager of Tetris Pharma Ltd
Helen has over 20 years of scientific, commercial and government affairs experience across several international biopharmaceutical companies. Before joining Tetris Pharma, Helen served as General Manager of Northern Markets (UK, Netherlands and Nordics) at Albireo Pharma, Inc., which was acquired by Ipsen in March 2023 and where she played a key role in establishing and building the regional affiliate.
READ MORE ↓READ LESS ↑Previously, Helen worked for 14 years at Gilead Sciences, where she held multiple positions, including Executive Director of EMEA, Global Affairs Regional Lead, where she was instrumental in broadening patient access to treatment. Whilst at Gilead, Helen led the launch of several transformational products in Europe developing critical launch strategies and expanding commercial opportunities.
Helen holds a BSc in Biology from York University, a PhD from Leeds University, and an MBA from Henley Management College.